Bristol Myers Squibb (BMY) announced that the Phase 3 ODYSSEY-HCM trial, which evaluated Camzyos or mavacamten for the treatment of adult patients with symptomatic New York Heart Association or NYHA class II-III non-obstructive hypertrophic cardiomyopathy or nHCM, did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2). No new safety signals were observed.
"While these results are disappointing, the ODYSSEY-HCM trial meaningfully contributes to the understanding of non-obstructive HCM, a disease where there remains a significant need for new treatment options," said Roland Chen, senior vice president, drug development, Immunology and Cardiovascular Medicines, Bristol Myers Squibb.
Bristol Myers Squibb noted that it will work with key investigators to share detailed results with the scientific community in the future.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.